Castle Biosciences, Inc. CSTL R2K

Healthcare · Diagnostics & Research · United States

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Market & Price

Market Cap

$639.36M

Current Price

$21.08

High / Low (52W)

$43.04 / $14.65

Beta

1.11

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

PEG Ratio

Book Value

$15.23

Price to Book

1.38

P/S

1.88

EV/EBITDA

-22.58

Dividend Yield

Profitability & Returns

ROCE

-5.77%

ROE

-2.85%

ROA

-3.96%

Profit Margin

-3.78%

Op Margin

-22.00%

EPS (Latest Qtr)

$-0.49

EPS (TTM)

$-0.42

Balance Sheet & Liquidity

Debt/Equity

0.08

Quick Ratio

6.26

Current Ratio

6.75

Debt

$36.72M

Total Assets

$578.56M

Current Assets

$361.10M

Working Capital

$292.42M

Ownership

Promoter Holding

2.73%

Chg in Prom Hold

FII / Inst Holding

93.00%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$414.39M

Total Revenue (TTM)

$339.92M

EBITDA

$-18.35M

Free Cash Flow

$12.89M

Operating Cash Flow

$48.25M

Shares Outstanding

30.33M

Gross Margin

77.88%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

35.94%

Profit 5Y

21.34%

Revenue (YoY)

-4.90%

Earnings (YoY)

PROS

Compounding revenue at 35.9% over 5 years.
Profit CAGR of 21.3% over 5 years.
Generates positive free cash flow.

CONS

Trading 51.0% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CSTL Castle Biosciences, Inc. R2K	21.08	-	$639.36M	-	-5.77%	-2.85%	35.94%	21.34%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	3.66M	3.98M	3.71M	11.44M	8.72M	10.74M	14.77M	17.64M	17.42M	12.71M	15.22M	17.30M	22.81M	22.76M	23.48M	26.85M	34.84M	37.01M	42.04M	50.14M	61.49M	72.97M	87.00M	85.78M	87.99M	86.19M	83.04M	87.01M	83.68M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.38M	17.63M	18.70M	18.32M	20.53M
Gross Profit	2.41M	2.65M	2.36M	10.07M	7.12M	8.75M	13.07M	15.62M	15.03M	10.57M	12.74M	14.63M	19.79M	-	-	-	-	-	-	-	-	-	-	-	71.61M	68.56M	64.34M	68.69M	63.15M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	99.53M	72.81M	71.14M	72.52M	81.55M
Operating Income	-	-2.67M	-2.85M	-	-322.00K	608.00K	4.43M	-	1.04M	-645.00K	-3.90M	-	-4.28M	-8.81M	-11.81M	-24.52M	-3.97M	-21.54M	-31.52M	-21.16M	-9.64M	-5.47M	5.01M	5.08M	-27.93M	-4.25M	-6.80M	-3.83M	-18.41M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.51M	3.29M	3.45M	1.09M	-10.35M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17.00K	21.00K	24.00K	24.00K	134.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-26.27M	-143.00K	-386.00K	-2.71M	-14.41M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-423.00K	-4.67M	115.00K	-382.00K	109.00K
Net Income	-3.63M	-3.15M	-3.45M	3.87M	-1.36M	-1.27M	5.85M	2.06M	570.00K	-1.38M	-4.59M	-4.89M	-4.28M	-8.79M	-11.79M	-24.62M	-1.65M	-20.25M	-29.20M	-18.78M	-6.91M	-2.53M	8.92M	2.27M	-25.85M	4.52M	-501.00K	-2.33M	-14.52M
Diluted EPS	-2.37	-2.15	-2.33	0.38	-1.22	-1.05	0.05	0.11	0.03	-0.08	-0.23	-0.23	-0.17	-0.35	-0.47	-0.97	-0.06	-0.77	-1.10	-0.70	-0.26	-0.09	0.31	0.08	-0.90	0.15	-0.02	-0.08	-0.49
R&D Expense	-	1.16M	1.29M	-	1.39M	1.32M	1.51M	-	2.91M	2.70M	3.06M	-	5.91M	6.79M	7.50M	10.76M	11.93M	10.91M	14.39M	13.31M	12.92M	13.81M	14.14M	12.32M	12.59M	12.79M	12.96M	-	14.43M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	22.79M	51.87M	62.65M	-	137.04M	219.79M	332.07M	344.23M
Cost of Revenue	-	-	-	-	32.01M	44.98M	60.20M	71.03M
Gross Profit	17.49M	44.55M	52.96M	-	105.03M	174.81M	271.86M	273.20M
Operating Expenses	-	-	-	-	196.17M	242.78M	263.19M	316.01M
Operating Income	-3.84M	7.33M	-6.54M	-	-91.14M	-67.98M	8.67M	-42.81M
EBITDA	-	-	-	-	-58.34M	-45.02M	38.14M	11.34M
Interest Expense	-	-	-	-	17.00K	11.00K	577.00K	86.00K
Pretax Income	-	-	-	-	-68.90M	-57.37M	21.56M	-29.51M
Tax Provision	-	-	-	-	-1.77M	101.00K	3.32M	-5.36M
Net Income	-6.37M	5.28M	-10.28M	-	-67.14M	-57.47M	18.25M	-24.16M
Diluted EPS	-5.33	-0.21	-0.54	-	-2.58	-2.14	0.62	-0.83
R&D Expense	4.85M	7.38M	13.26M	29.65M	44.90M	53.62M	52.04M	51.85M

Compounded Sales Growth

5 Years:	35.94%
1 Year:	-4.90%

Compounded Profit Growth

5 Years:	21.34%
1 Year:	-

Stock Price Performance

1 Year:	+32.00%
6 Months:	-47.21%
3 Months:	-28.71%
1 Month:	-13.04%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	22.41M	119.75M	439.33M	-	447.33M	453.34M	531.24M	578.56M
Current Assets	-	-	-	-	-	292.29M	295.63M	360.15M	361.10M
Cash & Equivalents	-	4.48M	98.84M	409.85M	-	122.95M	98.84M	119.71M	116.73M
Inventory	-	-	-	-	-	3.98M	7.94M	8.13M	10.25M
Receivables	-	-	-	-	-	23.48M	38.30M	51.22M	43.38M
Total Liabilities	-	32.48M	34.63M	23.64M	-	48.18M	62.07M	75.40M	107.68M
Current Liabilities	-	6.74M	15.29M	20.88M	-	36.13M	47.67M	49.39M	68.68M
Long Term Debt	-	24.50M	19.29M	0	-	-	-	9.74M	9.64M
Total Debt	-	-	-	-	-	13.40M	15.34M	26.34M	36.91M
Total Equity	-50.31M	-56.57M	85.11M	415.69M	-	399.15M	391.27M	455.83M	470.87M
Shares Outstanding	-	-	-	-	-	26.55M	27.41M	28.48M	29.69M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-12.29M	7.01M	9.87M	-	-41.66M	-5.63M	64.87M	64.35M
Investing Cash Flow	-277.00K	-937.00K	-4.75M	-	-166.54M	-16.18M	-50.14M	-60.37M
Financing Cash Flow	15.84M	88.29M	305.89M	-	1.51M	-2.30M	6.14M	-6.96M
Capital Expenditure	-277.00K	-937.00K	-4.75M	-	-5.63M	-13.62M	-28.33M	-36.02M
Free Cash Flow	-12.57M	6.08M	5.11M	-	-47.29M	-19.25M	36.54M	28.33M
Net Change in Cash	-	-	-	-	-206.69M	-24.11M	20.87M	-2.98M

Ratios (Annual)

Figures in %.

Metric	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	76.8%	85.9%	84.5%	-	76.6%	79.5%	81.9%	79.4%
Operating Margin %	-16.8%	14.1%	-10.4%	-	-66.5%	-30.9%	2.6%	-12.4%
Net Margin %	-27.9%	10.2%	-16.4%	-	-49.0%	-26.1%	5.5%	-7.0%
ROE %	11.3%	6.2%	-2.5%	-	-16.8%	-14.7%	4.0%	-5.1%
ROCE %	-24.5%	7.0%	-1.6%	-	-22.2%	-16.8%	1.8%	-8.4%

Shareholding Pattern

Insiders

2.73%

Institutions

93.00%

Public Float

95.61%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.83%	2.98M	$62.88M
2	RTW Investments LP	9.09%	2.76M	$58.15M
3	Principal Financial Group, Inc.	5.84%	1.77M	$37.31M
4	Portolan Capital Management, LLC	4.45%	1.35M	$28.46M
5	Vanguard Capital Management LLC	3.88%	1.18M	$24.82M
6	Dimensional Fund Advisors LP	3.43%	1.04M	$21.92M
7	Summit Partners Public Asset Management LLC	3.10%	940.68K	$19.83M
8	Vanguard Portfolio Management LLC	2.84%	861.77K	$18.17M
9	Allianz Asset Management GmbH	2.67%	811.32K	$17.10M
10	State Street Corporation	2.54%	769.08K	$16.21M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CSTL

No recent headlines available.

CSTL · Healthcare